CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

That widely missed Larew's estimate for $27.1 million. Chromium, 10x's oldest system, brought in $7.6 million. Its spatial ...

It believes Chromium will sustain “greater volume declines and/or pricing pressure than current management expectations, and thus perpetuate 10x Genomics’ margin degradation.” The bank sees ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

The Integrated Genomics Lab (IGL) provides support for single cell and nuclei DNA preparation and sequencing using the 10x Genomics Chromium single cell platform. The IGL maintains the Chromium ...

10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

Read more information on Single Cell & Transcriptomics Core services and our iLabs page. The 10X Chromium Controller processes up to 10,000 cells per lane. Cells, RT reagents and barcoded gel beads ...

Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments ... Co-founder and CEO of 10x Genomics.

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...